| 16/02/2023 |
Results of Institutional Entitlement Offer |
| 12/12/2016 |
CxBladder update |
| 29/11/2016 |
Cellmid Receives 831K R&D Tax Credit |
| 21/11/2016 |
AGM Presentation by CEO |
| 21/11/2016 |
Results of Annual General Meeting |
| 17/11/2016 |
Appendix 3Y – Change of Director’s Interest Notice |
| 09/11/2016 |
Cleansing Statement – Notice under section 708A(5)(e) of the Corporations Act |
| 03/11/2016 |
Usa Launch of Évolis® |
| 01/11/2016 |
Appendix 3Y- Change of Director’s Interest Notice |
| 01/11/2016 |
ASX Market Release – Reinstatement |
| 01/11/2016 |
Cellmid Capital Raising |
| 01/11/2016 |
Notes to Appendix 4C |
| 28/10/2016 |
Notes to the Appendix 3B |
| 26/10/2016 |
Trading Halt |
| 25/10/2016 |
Exercise of options (CDYO) |
| 21/10/2016 |
Appendix 3B – New issue announcement |
| 19/10/2016 |
Notice of Annual General Meeting |
| 18/10/2016 |
Change of Directors Interest Notice – Bruce Gordon |
| 18/10/2016 |
Change of Directors Interest Notice – David King |
| 18/10/2016 |
Change of Directors Interest Notice – Edward Fintan Walton |
| 18/10/2016 |
Change of Directors Interest Notice – Maria Halasz |
| 10/10/2016 |
Cellmid Records Highest Ever Quarterly Sales For Evolis® |
| 05/10/2016 |
Cellmid’s Midkine Antibodies Show Anti-tumor Activity Against Brain Cancer |
| 30/09/2016 |
2016 Annual Report |
| 28/09/2016 |
Quotation of Listed Options |
| 23/09/2016 |
Expiry of Listed Options (CDYO) |
| 22/09/2016 |
European Midkine Patent for Surgical Adhesion Allowed |
| 19/09/2016 |
Change of Directors Interest Notice – Maria Halasz |
| 13/09/2016 |
Date of Annual General Meeting |
| 31/08/2016 |
Appendix 4E and Preliminary Final Report |
| 31/08/2016 |
Appendix 4G – Corporate Governance Statement |
| 09/08/2016 |
New publication for Cellmid’s Midkine antibody |
| 03/08/2016 |
Cellmid Investor Presentation |
| 29/07/2016 |
Transcript of Cellmid Investor Briefing Call |
| 26/07/2016 |
Appendix 4C – quarterly |
| 22/07/2016 |
Ikon Legal Action |
| 21/07/2016 |
Cellmid Investor Briefing |
| 20/07/2016 |
USA Distribution Partnership for Cellmid’s évolis® |
| 29/06/2016 |
Midkine interviews with Pharmatelevision published |
| 24/06/2016 |
MK antibody publication and patent in bone healing |
| 20/06/2016 |
Change of Directors Interest Notice – Maria Halasz |
| 14/06/2016 |
évolis Professional Launch |
| 26/05/2016 |
Record monthly sales for Advangen Japan |
| 11/05/2016 |
4th MK Symposium Results |
| 09/05/2016 |
Significant scientific appointment for cellmid advisory board chair |
| 21/04/2016 |
Appendix 4C – quarterly |
| 08/04/2016 |
Midkine Strategy Update |
| 04/04/2016 |
Fourth Midkine Symposium to be held in Budapest |
| 26/02/2016 |
Cellmid to Refinance RnD Loan |
| 26/02/2016 |
Transcript of Cellmid Investor Briefing |
| 25/02/2016 |
Appendix 4D and Half Year Accounts |
| 23/02/2016 |
Cellmid Investor Briefing |
| 04/02/2016 |
Appointment of Elizabeth Masamune |
| 27/01/2016 |
Appendix 4C – quarterly |
